Elite Pharmaceuticals launches generic Requip XL; addresses $10M U.S. market

ELITE PHARMACEUTICALS INC /NV/

Launched generic Ropinirole Extended-Release Tablets (2, 4, 6, 8, 12 mg) for Parkinson's disease.
Product marketed under Elite Laboratories label; branded Requip XL and equivalents had $10M U.S. sales (IQVIA, 12 months ending June 2026).
Expands Elite's niche generic portfolio; company operates cGMP/DEA-registered facility in Northvale, NJ.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.